Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Ultragenyx Pharmaceutical Inc.
  6. Summary
    RARE

ULTRAGENYX PHARMACEUTICAL INC.

(RARE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/12/2021 04/13/2021 04/14/2021 04/15/2021 04/16/2021 Date
100.53(c) 106.59(c) 107.97(c) 109.58(c) 108.72(c) Last
556 049 456 572 251 681 208 910 376 430 Volume
-2.85% +6.03% +1.29% +1.49% -0.78% Change
More quotes
Financials (USD)
Sales 2021 329 M - -
Net income 2021 -354 M - -
Net cash position 2021 813 M - -
P/E ratio 2021 -20,4x
Yield 2021 -
Sales 2022 414 M - -
Net income 2022 -324 M - -
Net cash position 2022 621 M - -
P/E ratio 2022 -24,2x
Yield 2022 -
Capitalization 7 279 M 7 279 M -
EV / Sales 2021 19,7x
EV / Sales 2022 16,1x
Nbr of Employees 893
Free-Float 94,7%
More Financials
Company
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.... 
Read more
More about the company
Notations Surperformance© of Ultragenyx Pharmaceutical Inc.
Trading Rating : Investor Rating :
More Ratings
All news about ULTRAGENYX PHARMACEUTICAL INC.
04/16ULTRAGENYX PHARMACEUTICAL INC.  : Change in Directors or Principal Officers (for..
AQ
04/05N-LOREM FOUNDATION  : Partners with Ultragenyx to Bolster Development of Persona..
BU
03/08ULTRAGENYX PHARMACEUTICAL  : Receives FDA Clearance of Investigational NDA for U..
MT
03/08ULTRAGENYX PHARMACEUTICAL  : Announces FDA Clearance of Investigational New Drug..
AQ
03/03Ultragenyx to Present at Barclays Global Healthcare Conference
GL
03/02ULTRAGENYX PHARMACEUTICAL  : Stifel Reinstates Ultragenyx Pharmaceutical at Buy ..
MT
02/18ULTRAGENYX PHARMACEUTICAL  : Announces Approval of Dojolvi in Canada for the Tre..
AQ
02/17Ultragenyx to Present at Upcoming Investor Conferences
GL
02/17ULTRAGENYX PHARMACEUTICAL  : Obtains Canadian Approval of Dojolvi for Treatment ..
MT
02/17ULTRAGENYX PHARMACEUTICAL  : Announces Approval of Dojolvi™ (UX007/trihept..
AQ
02/16ULTRAGENYX PHARMACEUTICAL  : SVB Leerink Adjusts Ultragenyx Pharmaceutical's Pri..
MT
02/12ULTRAGENYX PHARMACEUTICAL  : Barclays Adjusts Ultragenyx Pharmaceutical PT to $1..
MT
02/12ULTRAGENYX PHARMACEUTICAL  : Piper Sandler Adjusts Ultragenyx Pharmaceutical PT ..
MT
02/12ULTRAGENYX PHARMACEUTICAL  : JPMorgan Downgrades Ultragenyx Pharmaceutical to Ne..
MT
02/12ULTRAGENYX PHARMACEUTICAL  : Wedbush Adjusts Price Target on Ultragenyx Pharmace..
MT
More news
News in other languages on ULTRAGENYX PHARMACEUTICAL INC.

- No features available -

More news
Analyst Recommendations on ULTRAGENYX PHARMACEUTICAL INC.
More recommendations
Stock Trading Strategies
ULTRAGENYX PHARMACEUTICAL INC. - 2020
The underlying trend is in force again
BUY
More Stock Trading Analysis
Chart ULTRAGENYX PHARMACEUTICAL INC.
Duration : Period :
Ultragenyx Pharmaceutical Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 160,19 $
Last Close Price 108,72 $
Spread / Highest target 79,4%
Spread / Average Target 47,3%
Spread / Lowest Target -8,94%
EPS Revisions
Managers and Directors
NameTitle
Emil D. Kakkis President, Chief Executive Officer & Director
Mardi C. Dier Chief Financial Officer & Executive Vice President
Daniel G. Welch Non-Executive Chairman
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Camille L. Bedrosian Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ULTRAGENYX PHARMACEUTICAL INC.-21.46%7 279
GILEAD SCIENCES, INC.12.89%84 193
VERTEX PHARMACEUTICALS INCORPORATED-7.17%56 783
REGENERON PHARMACEUTICALS, INC.2.39%52 343
WUXI APPTEC CO., LTD.-0.05%50 466
BIONTECH SE85.89%36 600
Categories
Free services
Mobile App
SOLUTIONS
About
Stock Market Quotes Interactive brokers The best of tweets Stock Market News Börse: Aktien, Kurse und Nachrichten
Copyright © 2021 Surperformance. All rights reserved. Stock quotes are provided by Factset, Morningstar and S&P Capital IQ